

ImmunID to Present at Biopartnering Europe

Grenoble, Lyon (France) – October 5, 2011 – ImmunID, the immune repertoire diversity company, will present at the **19th Annual BioPartnering Europe, QEII Conference Centre, London.**

On Tuesday, October 11, 2011 at Biopartnering Europe, Delphine Davan, in charge of Business Development Europe at ImmunID, will provide an introduction to the company's biomarker, divpenia[®], and on ImmunID's latest achievements in stratifying and monitoring patients suffering from Infectious Diseases and Cancer.

About Biopartnering Europe

Biopartnering Europe intends to connect and promote innovation within the European life science industry and to expand the global reach of companies and build sustainable profitable partnerships. For more information, please visit: <http://www.techvision.com/bpe/>

About ImmunID Technologies

Based in Grenoble and Lyon, France, ImmunID is a molecular diagnostics company that uses the immune repertoire diversity as a universal biomarker of health status and treatment efficiency. Indeed, patients with different levels of immune competence will have very different clinical outcomes. Based on this rationale, ImmunID's team is dedicated to bringing solutions for the assessment of the efficacy and safety of molecules during clinical trials and for patient stratification, in the areas of Oncology and Infectious Diseases. The company recently introduced the innovative concept of divpenia[®], a clinical state of reduced T & B lymphocytes immune diversity that correlates with a higher risk of infection & mortality and a reduced treatment efficiency. Divpenia[®] is detected by measuring the diversity of T and B lymphocyte receptors (TCR or BCR) using the ImmunTraCkeR[®] or Immun'Ig[®] tests. These tests allow the identification and characterization of V(D)J rearrangements on genomic DNA. ImmunID has gained a strong expertise in Solid Tumors and Hematological Malignancies during the clinical validation of divpenia[®]. The company is also providing immunomonitoring & stratification services to several biotech companies, pharmas and clinical research centers in additional indications, including HIV, HCV, and HSCT.

For further information on ImmunID and Divpenia[®], please visit the following websites:

www.immunid.com - www.divpenia.com

Contact

ImmunID Technologies

Phone: +33 (0)438 785 770

Fax: +33 (0)438 785 837

www.immunid.com

www.divpenia.com

Delphine Davan

Scientific Sales Manager – Europe

ddavan@immunid.com